Neoadjuvant Nivolumab a 'New Standard' in Lung Cancer

(MedPage Today) -- NEW ORLEANS -- The addition of the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy substantially improved event-free survival (EFS) in patients with operable non-small cell lung cancer (NSCLC), the...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news